SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

We support the overall FDA process for evaluating new antihyperglycemic drugs, which requires adequate data to demonstrate efficacy in lowering blood glucose and to provide reasonable assurance of ...

They found uptake of cardioprotective antihyperglycemic drugs—including glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors—increased over the 10-year study ...

When compared to DPP-4 inhibitors, this drug class reduced the risk by four for every 1,000 PY. Our research suggested that GLP-1 agonists were associated with a lower risk of dementia compared to ...

By Dr. Priyom Bose, Ph.D. Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and ...

As experience with these novel antihyperglycemic drugs increases, future studies with longer follow-up periods should be conducted to corroborate our findings. Patients were followed from cohort ...

GLP-1RAs are antihyperglycemic agents with protective ... GLP-1RAs would positively help physicians prescribe this class of drug for treatment. The current study used a discovery approach to ...